Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 23589569)

1.

MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.

Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken JC, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks C, Kamar Wang W, Döhner K, Jansen JH, Pahl HL.

J Exp Med. 2013 May 6;210(5):1003-19.

2.

A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.

Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayser S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL.

J Exp Med. 2012 Jan 16;209(1):35-50. doi: 10.1084/jem.20110540. Epub 2012 Jan 9.

3.

RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling.

Kapralova K, Lanikova L, Lorenzo F, Song J, Horvathova M, Divoky V, Prchal JT.

Blood. 2014 Jan 16;123(3):391-4. doi: 10.1182/blood-2013-10-534222. Epub 2013 Dec 2.

4.

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Wang W, Schwemmers S, Hexner EO, Pahl HL.

Blood. 2010 Jul 15;116(2):254-66. doi: 10.1182/blood-2009-11-254664. Epub 2010 Mar 25.

5.

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.

Grisouard J, Shimizu T, Duek A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC.

Blood. 2015 Mar 26;125(13):2131-40. doi: 10.1182/blood-2014-08-594572. Epub 2015 Jan 16.

PMID:
25595737
6.

Sumoylation of p45/NF-E2: nuclear positioning and transcriptional activation of the mammalian beta-like globin gene locus.

Shyu YC, Lee TL, Ting CY, Wen SC, Hsieh LJ, Li YC, Hwang JL, Lin CC, Shen CK.

Mol Cell Biol. 2005 Dec;25(23):10365-78.

7.

JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O'Brien S, Giles F, Bruey JM, Albitar M.

PLoS One. 2010 Aug 13;5(8):e12165. doi: 10.1371/journal.pone.0012165.

8.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW.

Blood. 2011 Dec 8;118(24):6392-8. doi: 10.1182/blood-2011-04-348144. Epub 2011 Aug 22.

9.

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.

Blood. 2010 Dec 23;116(26):5961-71. doi: 10.1182/blood-2009-12-256768. Epub 2010 Sep 24.

10.

3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice.

Ikeda K, Mason PJ, Bessler M.

Blood. 2011 Jun 2;117(22):5860-9. doi: 10.1182/blood-2011-02-334425. Epub 2011 Apr 1.

11.

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Jäger R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, Pietra D, Harutyunyan A, Klampfl T, Olcaydu D, Cazzola M, Kralovics R.

Leukemia. 2010 Jul;24(7):1290-8. doi: 10.1038/leu.2010.99. Epub 2010 May 27.

PMID:
20508609
12.

The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms.

Ikeda K, Ogawa K, Takeishi Y.

Fukushima J Med Sci. 2012;58(2):91-100. Review.

14.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.

15.

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.

Prick J, de Haan G, Green AR, Kent DG.

Exp Hematol. 2014 Oct;42(10):841-51. doi: 10.1016/j.exphem.2014.07.268. Epub 2014 Sep 6. Review.

PMID:
25201757
16.

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.

Amaru Calzada A, Todoerti K, Donadoni L, Pellicioli A, Tuana G, Gatta R, Neri A, Finazzi G, Mantovani R, Rambaldi A, Introna M, Lombardi L, Golay J; AGIMM Investigators.

Exp Hematol. 2012 Aug;40(8):634-45.e10. doi: 10.1016/j.exphem.2012.04.007. Epub 2012 May 8.

PMID:
22579713
17.

Physical and functional interactions between the transactivation domain of the hematopoietic transcription factor NF-E2 and WW domains.

Mosser EA, Kasanov JD, Forsberg EC, Kay BK, Ney PA, Bresnick EH.

Biochemistry. 1998 Sep 29;37(39):13686-95.

PMID:
9753456
18.

JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.

Irino T, Uemura M, Yamane H, Umemura S, Utsumi T, Kakazu N, Shirakawa T, Ito M, Suzuki T, Kinoshita K.

PLoS One. 2011;6(7):e22148. doi: 10.1371/journal.pone.0022148. Epub 2011 Jul 18.

20.

Regulation of NF-E2 activity in erythroleukemia cell differentiation.

Nagai T, Igarashi K, Akasaka J, Furuyama K, Fujita H, Hayashi N, Yamamoto M, Sassa S.

J Biol Chem. 1998 Feb 27;273(9):5358-65.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk